93 related articles for article (PubMed ID: 19854637)
1. Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.
Rocchetti M; Del Bene F; Germani M; Fiorentini F; Poggesi I; Pesenti E; Magni P; De Nicolao G
Eur J Cancer; 2009 Dec; 45(18):3336-46. PubMed ID: 19854637
[TBL] [Abstract][Full Text] [Related]
2. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
[TBL] [Abstract][Full Text] [Related]
3. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
4. Evaluating response to antineoplastic drug combinations in tissue culture models.
Reynolds CP; Maurer BJ
Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
[TBL] [Abstract][Full Text] [Related]
6. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
7. [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2263-70. PubMed ID: 1929447
[TBL] [Abstract][Full Text] [Related]
8. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
Choo EF; Ng CM; Berry L; Belvin M; Lewin-Koh N; Merchant M; Salphati L
Cancer Chemother Pharmacol; 2013 Jan; 71(1):133-43. PubMed ID: 23053270
[TBL] [Abstract][Full Text] [Related]
9. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
10. Predicting the active doses in humans from animal studies: a novel approach in oncology.
Rocchetti M; Simeoni M; Pesenti E; De Nicolao G; Poggesi I
Eur J Cancer; 2007 Aug; 43(12):1862-8. PubMed ID: 17604156
[TBL] [Abstract][Full Text] [Related]
11. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
Toutain PL; Lees P
J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
[TBL] [Abstract][Full Text] [Related]
12. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
Teicher BA
Curr Opin Pharmacol; 2010 Aug; 10(4):397-404. PubMed ID: 20547104
[TBL] [Abstract][Full Text] [Related]
13. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
Lees P; Giraudel J; Landoni MF; Toutain PL
J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
15. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Terranova N; Germani M; Del Bene F; Magni P
Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
[TBL] [Abstract][Full Text] [Related]
16. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
17. Modeling of tumor growth and anticancer effects of combination therapy.
Koch G; Walz A; Lahu G; Schropp J
J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):179-97. PubMed ID: 19387803
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Trédan O; Garbens AB; Lalani AS; Tannock IF
Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
[TBL] [Abstract][Full Text] [Related]
20. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
Delavenne X; Laporte S; Demasles S; Mallouk N; Basset T; Tod M; Girard P; Mismetti P
Fundam Clin Pharmacol; 2009 Feb; 23(1):127-35. PubMed ID: 19267776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
